Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

Trial Profile

C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brain extract (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms C-REGS2
  • Sponsors EVER Neuro Pharma
  • Most Recent Events

    • 14 Oct 2019 Planned End Date changed from 30 Mar 2021 to 30 May 2021.
    • 14 Oct 2019 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.
    • 06 Feb 2019 Planned End Date changed from 30 Sep 2020 to 30 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top